Clinical outcomes of valganciclovir prophylaxis in high-risk (D+/R-) renal transplant recipients experiencing delayed graft function.

Sari R Freedman Bharath R Ravichandran Brian M Masters Jonathan S Bromberg Abdolreza HaririanKapil K SahariaEmily L Heil Tracy M Sparkes

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2019)

Valganciclovir prophylaxis in patients experiencing DGF yielded similar CMV outcomes up to 1-year post transplant when compared to use in patients with IGF.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
adipose tissue
binding protein
skeletal muscle
insulin resistance
weight loss